Stockscreener 앱 받기
1.55
3.73%
-0.06
전일 마감가:
$1.61
열려 있는:
$1.62
하루 거래량:
168.95K
Relative Volume:
2.41
시가총액:
$74.80M
수익:
$9.16M
순이익/손실:
$-68.17M
주가수익비율:
-0.9118
EPS:
-1.7
순현금흐름:
$-80.16M
1주 성능:
-6.06%
1개월 성능:
-8.82%
6개월 성능:
-6.63%
1년 성능:
-20.51%
1일 변동 폭
$1.55
$1.62
1주일 범위
$1.52
$1.665
52주 변동 폭
$1.22
$2.30
아이케나 온콜로지 Stock (IKNA) Company Profile
명칭
Ikena Oncology Inc
전화
857-343-8292
주소
50 NORTHERN AVE., BOSTON
IKNA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IKNA
Ikena Oncology Inc
|
1.55 | 74.80M | 9.16M | -68.17M | -80.16M | -1.63 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
아이케나 온콜로지 Stock (IKNA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-05-29 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2023-09-22 | 개시 | Wedbush | Outperform |
| 2023-05-04 | 재개 | H.C. Wainwright | Buy |
| 2021-12-23 | 개시 | H.C. Wainwright | Buy |
| 2021-05-05 | 재개 | Credit Suisse | Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-04-20 | 개시 | Credit Suisse | Outperform |
| 2021-04-20 | 개시 | Jefferies | Buy |
| 2021-04-20 | 개시 | William Blair | Outperform |
모두보기
아이케나 온콜로지 주식(IKNA)의 최신 뉴스
Ikena Oncology, Inc. (NASDAQ:IKNA) Short Interest Update - MarketBeat
Ikena Oncology FY2024 EPS Estimate Boosted by HC Wainwright - Defense World
Ikena Oncology FY2024 EPS Forecast Lifted by HC Wainwright - MarketBeat
3 US Penny Stocks With Market Caps Over $40M To Consider - Simply Wall St
Ikena Oncology (NASDAQ:IKNA) Earns “Buy” Rating from HC Wainwright - Defense World
Ikena Oncology (NASDAQ:IKNA) Given "Buy" Rating at HC Wainwright - MarketBeat
Ikena Oncology Third Quarter 2024 Earnings: US$0.21 loss per share (vs US$0.40 loss in 3Q 2023) - Yahoo Finance
Wedbush Reaffirms “Neutral” Rating for Ikena Oncology (NASDAQ:IKNA) - Defense World
Ikena Oncology Reports Strategic Realignment and Financial Performance - TipRanks
Ikena Oncology Reports Third Quarter 2024 Financial Results - GlobeNewswire
Ikena Oncology Reports 41% Lower Net Loss, Strong $138M Cash Position in Q3 | IKNA Stock News - StockTitan
Renaissance Technologies LLC Sells 300,200 Shares of Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
Point72 Asia Singapore Pte. Ltd. Invests $75,000 in Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
Ikena Oncology’s Gamble: Slashing Workforce by Half Could Derail Strategic Plans - TipRanks
Point72 Asia Singapore Pte. Ltd. Purchases Shares of 45,520 Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
Acadian Asset Management LLC Has $536,000 Stake in Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
Analyzing Ikena Oncology (NASDAQ:IKNA) & Kiromic BioPharma (NASDAQ:KRBP) - Defense World
Ikena Oncology, Inc. (NASDAQ:IKNA) Sees Large Drop in Short Interest - MarketBeat
Ikena Oncology, Inc. (NASDAQ:IKNA) Short Interest Down 10.7% in July - Defense World
On Ikena Oncology ($IKNA) Setting up a Sale - substack.com
Q3 2024 EPS Estimates for Ikena Oncology, Inc. (NASDAQ:IKNA) Lifted by HC Wainwright - MarketBeat
Ikena Oncology, Inc. (NASDAQ:IKNA) Expected to Post Q3 2024 Earnings of ($0.26) Per Share - Defense World
HC Wainwright Reaffirms "Buy" Rating for Ikena Oncology (NASDAQ:IKNA) - MarketBeat
Ikena Oncology (NASDAQ:IKNA) Receives Buy Rating from HC Wainwright - Defense World
Ikena Oncology (NASDAQ:IKNA) Announces Quarterly Earnings Results, Beats Estimates By $0.04 EPS - Defense World
Ikena Oncology Reports Second Quarter 2024 Financial Results - GlobeNewswire
Jacobs Levy Equity Management Inc. Increases Holdings in Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
Jacobs Levy Equity Management Inc. Boosts Holdings in Ikena Oncology, Inc. (NASDAQ:IKNA) - MarketBeat
Acadian Asset Management LLC Raises Position in Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
Ikena Oncology, Inc. (NASDAQ:IKNA) Sees Significant Decline in Short Interest - MarketBeat
Ikena Oncology to Present Preclinical Findings on IK-930, a Novel TEAD Inhibitor at the 2022 American Association for Cancer Research (AACR) Annual Meeting - Barchart
Ikena Oncology, Inc. (NASDAQ:IKNA) Sees Significant Drop in Short Interest - Defense World
Ikena Oncology expands role of CFO Jotin Marango to COO - Investing.com
Ikena Oncology Promotes Jotin Marango to Chief Operating Officer - TipRanks
New Strong Buy Stocks for July 12th - Yahoo Finance
Down -29.05% in 4 Weeks, Here's Why Ikena Oncology, Inc. (IKNA) Looks Ripe for a Turnaround - MSN
Take off with Ikena Oncology Inc (IKNA): Get ready for trading – Sete News - SETE News
Short Interest in Ikena Oncology, Inc. (NASDAQ:IKNA) Decreases By 9.0% - MarketBeat
Fierce Biotech Layoff Tracker 2024: Takeda axes another 220 jobs; Ovid undergoes 43% reduction - Fierce Biotech
Ikena Oncology - The Pharma Letter
HC Wainwright & Co. Reiterates Ikena Oncology (IKNA) Buy Recommendation - MSN
Why Ikena Oncology (IKNA) Might Surprise This Earnings Season - Yahoo News Malaysia
Head and Neck cancer Pipeline Forecast 2024: FDA Approvals, - openPR
Ikena Oncology Reports First Quarter 2022 Financial Results and Provides a Corporate Update - Quantisnow
Ikena Oncology Announces $40 Million Underwritten Offering - Quantisnow
Ikena Oncology to Participate in Cowen 42nd Annual Health Care Conference - Quantisnow
Ikena Oncology to Participate in the William Blair Biotech Focus Conference 2022 - Quantisnow
Seismic Therapeutic Appoints Maude Tessier, PhD, as Chief Business Officer - Quantisnow
Ikena Oncology to Participate in the Piper Sandler 34th Annual Healthcare Conference - Quantisnow
Ikena Oncology (NASDAQ:IKNA shareholders incur further losses as stock declines 16% this week, taking one-year ... - Yahoo Movies UK
Ikena Oncology, Inc.'s (NASDAQ:IKNA) largest shareholders are private equity firms with 46% ownership, institutions ... - Yahoo Canada Sports
아이케나 온콜로지 (IKNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.88%
2.65%
자본화:
|
볼륨(24시간):